A drug for the treatment of cancer

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 38/31 (2006.01) A61K 38/00 (2006.01) A61K 38/08 (2006.01) A61K 38/10 (2006.01) A61K 38/17 (2006.01) A61K 38/22 (2006.01) A61K 38/27 (2006.01) A61K 45/00 (2006.01)

Patent

CA 2197139

A pharmaceutical composition useful for killing or inhibiting multiplication of cancer cells. It is expected that the pharmaceutical composition will be useful in preventing, inhibiting, or modulating the hypersecretion of VIP, somatostatin, bombesin, Substance P, or a combination of VIP, somatostatin, bombesin, or Substance P. The composition may suitably comprise, consist of, or consist essentially of a therapeutically effective combination of peptide analogs of somatostatin, VIP, bombesin and Substance P. Also provided is a method of treatment for humans or other animals suffering from cancer, the method comprising administering a therapeutically effective dose of the pharmaceutical composition so as to kill or inhibit the multiplication of cancer cells. The method of treatment may be particularly useful in the treatment of cancers of the colon and rectum. Also provided is a method of treatment for humans or animals having hypersecretion or modulation of VIP, somatostatin, bombesin, Substance P, or a combination of VIP, somatostatin, bombesin, or Substance P.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

A drug for the treatment of cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with A drug for the treatment of cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and A drug for the treatment of cancer will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1493865

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.